(Alliance News) - AstraZeneca PLC on Tuesday said its therapy for hypertension demonstrated positive results in a recent phase 3 trial, while its breast cancer therapy is put forward for review in ...
Doctors say they're seeing breast cancer survivors live longer amid an explosion of new treatment options. Dr. David Riseberg ...
Claudine Isaacs, MD: For this patient who's progressed after more than 12 months with an ESR1 mutation and HER2-low disease ...
Capital Market on MSN
AstraZeneca Pharma gets CDSCO nod for Enhertu
Through this approval, Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder is indicated for the treatment of adult ...
October 2025 Datroway demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer ...
Findings from DESTINY-Breast11 showed T-DXd followed by THP demonstrated a statistically significant and clinically meaningful improvement in pCR rate vs ddAC-THP.
Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...
AstraZeneca and Daiichi Sankyo announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority ...
Daiichi Sankyo & AstraZeneca’s sBLA for Enhertu followed by THP accepted in US for patients with high-risk HER2 positive early-stage breast cancer prior to surgery: Tokyo Friday ...
The Phase III DESTINY-Breast05 trial demonstrated that trastuzumab deruxtecan (Enhertu) significantly improved invasive ...
The FDA has granted fast track designation to ETX-636, a pan mutant-specific allosteric PIK3CA inhibitor, for the treatment of patients with PIK3CA -mutant, hormone receptor (HR)-positive (+), ...
Patients with HER2-positive tumors fared better on neoadjuvant Enhertu followed by chemo and a dual anti-HER2 antibody regimen than those on standard treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback